> Chemicals & Drugs > Organic Chemical > 1,4,7-triazacyclononane-N,N',N''-triacetic acid

1,4,7-triazacyclononane-N,N',N''-triacetic acid

1,4,7-Triazacyclononane-N,N',N''-Triacetic Acid: A heterocyclic compound composed of a 9-membered ring containing three nitrogen atoms and three acetic acid groups attached to the nitrogens.
It is used as a chelating agent and in the preparation of radiopharmaceuticals for medical imaging and therapy.
This versatile molecule has applications in chemistry, biology, and medicine.

Most cited protocols related to «1,4,7-triazacyclononane-N,N',N''-triacetic acid»

Fetal Brain Tissue Acquisition and Processing

Tissue was provided by the Birth Defects Research Laboratory (BDRL) at the University of Washington and Advanced Bioscience Resources Incorporated (ABR; Alameda, CA). All work was performed according to guidelines for the research use of human brain tissue (ABR) or the UAGA and NOTA guidelines for the acquisition and distribution of human tissue for bio-medical research purposes (BDRL) and with approval by the Human Investigation Committees and Institutional Ethics Committees of each institute from which samples were obtained. Appropriate written informed consent was obtained and all available non-identifying information was recorded for each sample. Specimens for microarray profiling consisted of two 21 pcw females, one 15 pcw male and one 16 pcw female (Suppl. Table 1).

Miller J.A., Ding S.L., Sunkin S.M., Smith K.A., Ng L., Szafer A., Ebbert A., Riley Z.L., Aiona K., Arnold J.M., Bennet C., Bertagnolli D., Brouner K., Butler S., Caldejon S., Carey A., Cuhaciyan C., Dalley R.A., Dee N., Dolbeare T.A., Facer B.A., Feng D., Fliss T.P., Gee G., Goldy J., Gourley L., Gregor B.W., Gu G., Howard R.E., Jochim J.M., Kuan C.L., Lau C., Lee C.K., Lee F., Lemon T.A., Lesnar P., McMurray B., Mastan N., Mosqueda N.F., Naluai-Cecchini T., Ngo N.K., Nyhus J., Oldre A., Olson E., Parente J., Parker P.D., Parry S.E., Player A.S., Pletikos M., Reding M., Royall J.J., Roll K., Sandman D., Sarreal M., Shapouri S., Shapovalova N.V., Shen E.H., Sjoquist N., Slaughterbeck C.R., Smith M., Sodt A.J., Williams D., Zöllei L., Fischl B., Gerstein M.B., Geschwind D.H., Glass I.A., Hawrylycz M.J., Hevner R.F., Huang H., Jones A.R., Knowles J.A., Levitt P., Phillips J.W., Sestan N., Wohnoutka P., Dang C., Bernard A., Hohmann J.G, & Lein E.S. (2014). Transcriptional Landscape of the Prenatal Human Brain. Nature, 508(7495), 199-206.

Publication 2014

1,4,7-triazacyclononane-N,N',N''-triacetic acid Brain congenital defects Females Homo sapiens Institutional Ethics Committees Males Microarray Analysis Tissues

In Vivo Evaluation of 64Cu-NOTA-GO-TRC105 in 4T1 Murine Breast Tumor

All animal studies were conducted under a protocol approved by the University of Wisconsin Institutional Animal Care and Use Committee. PET and PET/CT scans at various time points p.i. using a microPET/microCT Inveon rodent model scanner (Siemens Medical Solutions USA, Inc.), image reconstruction, and ROI analysis of the PET data were performed similar as described previously (see Supporting Information for details).^{49 (link), 50 (link)} Quantitative PET data were presented as percentage injected dose per gram of tissue (%ID/g).
4T1 murine breast tumor-bearing mice, a fast-growing tumor model with high CD105 expression on the tumor vasculature,^{41 (link), 42 (link), 50 (link)} were each injected with 5–10 MBq of ⁶⁴Cu-NOTA-GO-TRC105 or ⁶⁴Cu-NOTA-GO via tail vein before serial PET scans. Another group of four 4T1 tumor-bearing mice were each injected with 2 mg of unlabeled TRC105 at 2 h before ⁶⁴Cu-NOTA-GO-TRC105 administration to evaluate the CD105 specificity of ⁶⁴Cu-NOTA-GO-TRC105 in vivo (i.e. blocking experiment). To generate the 4T1 tumor model, 4- to 5-week-old female Balb/c mice were purchased from Harlan (Indianapolis, IN, USA) and tumors were established by subcutaneously injecting 2×10⁶ cells, suspended in 100 μl of 1:1 mixture of RPMI 1640 and Matrigel (BD Biosciences, Franklin Lakes, NJ, USA), into the front flank of mice. The tumor sizes were monitored every other day and the animals were subjected to in vivo experiments when the tumor diameter reached 5–8 mm.
After the last PET scans at 48 h p.i., biodistribution studies were carried out to confirm that the %ID/g values based on PET imaging truly represented the radioactivity distribution in tumor-bearing mice. In addition, separate groups of four 4T1 tumor-bearing mice were each intravenously injected with ⁶⁴Cu-NOTA-GO-TRC105 or ⁶⁴Cu-NOTA-GO and euthanized at 3 h p.i. (when tumor uptake was at the peak based on PET results) for biodistribution studies. Mice were euthanized and blood, 4T1 tumor, and major organs/tissues were collected and wet-weighed. The radioactivity in the tissue was measured using a gamma-counter (Perkin Elmer) and presented as %ID/g (mean ± SD).

Hong H., Yang K., Zhang Y., Engle J.W., Feng L., Yang Y., Nayak T.R., Goel S., Bean J., Theuer C.P., Barnhart T.E., Liu Z, & Cai W. (2012). In Vivo Targeting and Imaging of Tumor Vasculature with Radiolabeled, Antibody-Conjugated Nano-Graphene. ACS Nano, 6(3), 2361-2370.

Publication 2012

1,4,7-triazacyclononane-N,N',N''-triacetic acid Animals Bears BLOOD Breast Neoplasm Cells Gamma Rays Institutional Animal Care and Use Committees matrigel Mice, Inbred BALB C Mus Neoplasms Radioactivity Radionuclide Imaging Rodent Scan, CT PET Tail Tissues TRC105 Veins Woman X-Ray Microtomography

In Vivo PET Imaging of Murine Breast Cancer

The 4T1 murine breast cancer model was generated as previously described [13 (link), 29 (link)]. PET and PET/CT scans of tumor-bearing female BALB/c mice (6–8 weeks old, tumor diameter 5–8 mm) were performed using an Inveon microPET/microCT rodent model scanner (Siemens Medical Solutions USA, Inc.). Each mouse was intravenously injected with 5–10 MBq of ^61/64Cu-NOTA-TRC105-Fab and 5 or 10 minute static PET scans were performed at various time points post-injection (p.i.). The images were reconstructed using a maximum a posteriori (MAP) algorithm, with no attenuation or scatter correction. Region-of-interest (ROI) analysis of each PET scan was performed using vendor software (Inveon Research Workplace [IRW]) on decay-corrected whole-body images as described previously [30 (link), 31 (link)], to calculate the percentage injected dose per gram of tissue (%ID/g) values for the 4T1 tumor and several major organs.
Blocking studies were carried out to evaluate CD105 specificity of ⁶⁴Cu-NOTA-TRC105-Fab in vivo, where a group of 4 mice was each injected with 2 mg of TRC105 within 1 h before ⁶⁴Cu-NOTA-TRC105-Fab administration. After the last PET scans at 24 h p.i., mice were euthanized and the blood, 4T1 tumor, and major organs/tissues were collected and wet-weighed. The radioactivity in the tissue was measured using a Cobra II gamma-counter (Perkin-Elmer) and presented as %ID/g. The 4T1 tumor, liver, kidney (i.e. tissues with significant uptake of ^61/64Cu-NOTA-TRC105-Fab), and muscle were also frozen and sectioned for histological analysis.

Zhang Y., Hong H., Orbay H., Valdovinos H.F., Nayak T.R., Theuer C.P., Barnhart T.E, & Cai W. (2013). PET Imaging of CD105/Endoglin Expression with a 61/64Cu-Labeled Fab Antibody Fragment. European journal of nuclear medicine and molecular imaging, 40(5), 759-767.

Publication 2013

1,4,7-triazacyclononane-N,N',N''-triacetic acid BLOOD Body Image Breast Carcinoma Cardiac Arrest Cobra Freezing Gamma Rays Kidney Liver Mice, Inbred BALB C Mus Muscle Tissue Neoplasms Positron-Emission Tomography Radioactivity Radionuclide Imaging Rodent Scan, CT PET Tissues TRC105 Woman X-Ray Microtomography

Synthesis of NOTA-GO-TRC105 Conjugate

GO-PEG-NH₂ was mixed with S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA) or FITC, which has the same chemical reaction between the SCN group and the NH₂ group on GO, at a molar ratio of 1:10 at pH 9.0 for 2 h. The resulting NOTA-GO (or FITC-GO) was purified by centrifugation filtration using 100 kDa cutoff Amicon filters (15 minutes at 12,520 g). NOTA-GO (or FITC-GO) was subsequently reacted with succinimidyl carboxymethyl PEG maleimide (SCM-PEG-Mal) at pH 8.5 at a molar ratio of 1:30 for 2 h. After removing the unreacted SCM-PEG-Mal and other reagents by centrifugation filtration, the resulting reaction intermediates were named as NOTA-GO-Mal or FITC-GO-Mal.
Meanwhile, TRC105 was mixed with Traut’s reagent at a molar ratio of 1:25 at pH 8.0. After 2 h of incubation at room temperature (RT), the resulting TRC105-SH was purified by size exclusive chromatography using phosphate-buffered saline (PBS, pre-treated with Chelex 100 resin to prevent oxidation of the thiol) as the mobile phase. With this reaction ratio, we calculated that there are about 8 thiol groups per TRC105 molecule based on Ellman’s reagent titration (see Supporting Information Figure S2). Subsequently, NOTA-GO-Mal or FITC-GO-Mal was mixed with TRC105-SH at a molar ratio of 1:5 at pH 7.5 in the presence of tris(2-carboxyethyl)phosphine (i.e. TCEP) to avoid disulfide formation between TRC105-SH. The final products were purified by centrifugation filtration as described above and termed NOTA-GO-TRC105 and FITC-GO-TRC105.

Publication 2012

1,4,7-triazacyclononane-N,N',N''-triacetic acid Acids Centrifugation Chelex 100 Chromatography Disulfides Dithionitrobenzoic Acid Filtration Fluorescein-5-isothiocyanate maleimide Molar Phosphates phosphine Resins, Plant Saline Solution Sulfhydryl Compounds Titrimetry TRC105 triazacyclononane tris(2-carboxyethyl)phosphine Tromethamine

Live Imaging of Notum Development

Notum live imaging was performed as described previously [3 (link)]. Briefly, the pupae were collected at the early stage (0–6 h after pupal formation), aged at 29^∘C, glued on double sided tape on a slide and surrounded by two metal spacers of approx. 0.650 mm. The pupal case was opened up to the abdomen using forceps and mounted with a 20 × 40 mm #1.5 coverslip where we buttered halocarbon oil 10S. The coverslip was then tapped on the spacers using regular tape. Pupae were collected 48 or 72 h after clone induction and dissected 16-18h after pupae formation (APF). Pupae were imaged at 29^∘C for 22 h on a LSM 880 scanning laser confocal microscope (Carl Zeiss A.G.) equipped with a fast Airyscan module using an oil 40X objective (NA 1.3), Z stacks (1 μm/slice), every 5 min using autofocus. The autofocus was performed using the autofluorescence of the cuticle in far red (using a Zen Macro developed by Jan Ellenberg laboratory, MyPic). Movies were performed in the nota close to the scutellum region containing the midline and the aDC and pDC macrochaetae. The experiment presents a pupae with endoCad::GFP signal and groups of cell over-expressing UAS-yorkie S11A S168A S250A V5 clones and nuclei in red over the control of the GAL80TS thermosensitive. The cross and the progeny were kept at 18^∘C, and the pupae were switched to 29^∘C 8 h prior to the movie for conditional activation.

Herbert S., Valon L., Mancini L., Dray N., Caldarelli P., Gros J., Esposito E., Shorte S.L., Bally-Cuif L., Aulner N., Levayer R, & Tinevez J.Y. (2021). LocalZProjector and DeProj: a toolbox for local 2D projection and accurate morphometrics of large 3D microscopy images. BMC Biology, 19, 136.

Full text: Click here

Publication 2021

1,4,7-triazacyclononane-N,N',N''-triacetic acid Abdomen Cells Clone Cells Forceps Metals Microscopy, Confocal, Laser Scanning Pupa Red Nucleus

Most recents protocols related to «1,4,7-triazacyclononane-N,N',N''-triacetic acid»

In Vivo PET/CT Imaging of Tumor Xenografts

Not available on PMC !

Example 9

In vivo PET/CT imaging was conducted in NCr nude mice bearing bxpc3 (human pancreatic adenocarcinoma cell line) and 4T1 (a murine breast cancer cell line that overexpresses integrin α_vβ3 and CD13) tumor xenografts.

Mice were injected with bxpc3 cells (1 million cells in 150 μL PBS) into the subcutaneous flank of the right shoulder and 4T1 cells (1 million cells in 150 μL PBS) into the subcutaneous flank of the left shoulder. Either the CNGRC-(⁶⁸Ga)NOTA-RGDyK heterodimer (“CNGRC” disclosed as SEQ ID NO: 1), (⁶⁸Ga)NOTA(CNGRC) (“CNGRC” disclosed as SEQ ID NO: 1), or (⁶⁸Ga)NOTA(RGDyK) were injected into the bloodstream via tail vein injection. Blocking studies were conducted for the heterodimer studies by co-injecting 100 times of cyclo(CNGRC) (“CNGRC” disclosed as SEQ ID NO: 1) and cyclo(RGDyK). Small animal PET/CT was performed at 1 hour post injection of tracers (FIG. 14). The heterodimer CNGRC-(⁶⁸Ga)NOTA-RGDyK (“CNGRC” disclosed as SEQ ID NO: 1) showed improved enhanced in in vivo performance (such as longer blood retention, better tumor/non-tumor ratios).

US11857648B2. Dimerization strategies and compounds for molecular imaging and/or radioimmunotherapy (2024-01-02). UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION [US]. Inventors: Dexing Zeng [US], Lingyi Sun [US], Yongkang Gai [US].

Full text: Click here

Patent 2024

1,4,7-triazacyclononane-N,N',N''-triacetic acid Adenocarcinoma Animals BLOOD Blood Circulation Cardiac Arrest Cell Lines Cells Homo sapiens Integrin alphaVbeta3 MCF-7 Cells Mice, Nude Mus Neoplasms Pancreas Retention (Psychology) Scan, CT PET Shoulder Tail Veins Xenografting

Optimizing Targeted Molecular Probe Avidity

Not available on PMC !

Example 14

Eight NH₂—PEG_n-RGD peptides containing spacers of various PEG lengths (n=2, 4, 6, 8, 10, 12, 14, 16) will be prepared by adding the corresponding Boc-PEG_n-NHS to RGD in a PBS buffer (pH=8.2), followed by Boc deprotection. Photo-ODIBO-NHS, prepared using previously reported procedures, will then be mixed with the prepared NH₂—PEG_n-RGD in a PBS buffer (pH=8.2) to produce photo-OIDBO-PEG_n-RGD. N₃-PEG₄-cetuximab will be prepared using previously reported procedures. N₃—PEG₄-cetuximab and the eight photo-ODIBO-PEG_n-RGD peptides (n=2, 4, 6, 8, 10, 12, 14, 16) will be used for in vitro screening (at 4° C. to minimize the internalization of targeting probes). As shown in FIG. 11: 1): eight mixed-ligands stock solutions will be prepared by mixing N₃-PEG₄-cetuximab with one of the eight photo-OIDBO-PEG_n-RGD peptides; 2) U87MG cells will be cultured in a 96-well plate; 3) one of the above eight mixed-ligands stock solution will be added into each well (eight wells in total) pre-seeded with U87MG; 2) after the ligands bind to the targeted receptors, the excess (unbound) targeting ligands will be washed off using a PBS buffer (repeated 5 times to ensure complete removal); 3) a UV lamp (365 nm) will be applied to deprotect the azide-inactive photo-ODIBO and generate azide-active “ODIBO”, subsequently triggering ligation between the N₃-PEG₄-cetuximab and ODIBO-PEG_n-RGD; 4) after being incubated for an additional 2 h, ⁶⁴Cu-labeled N₃—NOTA will be added to click with the “excess” ODIBO-PEG_n-RGD (that binds to cells, but does not click to N₃-PEG₄-cetuximab); and 5) the excess N₃-(⁶⁴Cu)NOTA will be removed, and the N₃-(⁶⁴Cu)NOTA clicked to “excess” ODIBO-PEG_n-RGD will be measured on MicroBeta2 Plate Counter. One group without UV irradiation will be used as a negative control to get counts from the non-specific binding of N₃-(⁶⁴Cu)NOTA. After subtracting the non-specific binding, the specific binding of N₃-(⁶⁴Cu)NOTA obtained from the eight ODIBO-PEG_n-RGD (n=2, 4, 6, 8, 10, 12, 14, 16) will be compared. The well with the lowest specific binding will contain the highest amount of clicking product (between cetuximab-PEG₄-N₃and ODIBO-PEG_n-RGD), thus the corresponding spacer will be the most potent.

The ODIBO-PEG_n-RGD containing the most potent PEG spacer will click with Tz-NOTA-N₃and then be radiolabeled with ⁶⁴Cu, and the resulting Tz-(⁶⁴Cu)NOTA-PEG_n-RGD will be used for the in vitro avidity studies on U87MG cells. Tz-(⁶⁴Cu)NOTA-RGD (without a PEG spacer) will be used as a negative control because the distance between RGD and cetuximab in the resulting heterodimer is too short to achieve avidity effect (proved in preliminary study, FIG. 5B). Briefly, Tz-(⁶⁴Cu)NOTA-PEG_n-RGD/TCO-PEG₄-cetuximab ligation product (cetuximab-PEG₄-(⁶⁴Cu)NOTA-PEG_n-RGD) will be used for cell uptake/efflux, binding affinity and Bmax measurements on U87MG cells. After high avidity effect is confirmed on the above ligation product, in vivo evaluation will be performed then. Mice bearing U87MG xenografts will be pre-injected with 100 μg of TCOPEG₄-cetuximab, and 24 h later, ˜250-350 pCi of Tz-(⁶⁴Cu)NOTA-PEG_n-RGD (or Tz-(⁶⁴Cu)NOTA-RGD in the negative control group) will be injected. Then 1 h dynamic PET scans will be performed at multiple time points (p.i., 4, 18, and/or 28 h). As cetuximab is cleared through the liver, kinetics on tumor and liver at mid and late time points can be evaluated. At mid/late time points (4, 18, 28 h) when most of the un-ligated Tz-(⁶⁴Cu)NOTAPEGn-RGD has been washed off, observation of relatively slower tumor washing out and faster liver clearing (compared to that from Tz-(⁶⁴Cu)NOTA-RGD) can indicate the much stronger binding with tumor cells, and thus an avidity effect of in vivo ligation product (cetuximab-PEG₂-(⁶⁴Cu)NOTA-PEG_n-RGD) is being achieved.

Various references are cited in this document, which are hereby incorporated by reference in their entireties herein.

Full text: Click here

Patent 2024

1,4,7-triazacyclononane-N,N',N''-triacetic acid Azides Buffers Cells Cetuximab Heterografts Kinetics Ligands Ligation Liver Mus Neoplasms Peptides Positron-Emission Tomography Ultraviolet Rays

In vivo PET/CT Imaging of Orthotopic Pancreatic Tumor

Not available on PMC !

Example 10

In vivo PET/CT imaging was conducted in Balb/c mice. One week after the orthotropic implantation of 1×10⁶luciferase-transfected KPCP cancer cells into the pancreas of Balb/c mice, the mice were used for PET imaging. Either the CNGRC-(⁶⁸Ga)NOTA-RGDyK heterodimer (“CNGRC” disclosed as SEQ ID NO: 1), (⁶⁸Ga)NOTA(CNGRC) (“CNGRC” disclosed as SEQ ID NO: 1), or (⁶⁸Ga)NOTA(RGDyK)] were injected into the bloodstream via tail vein injection. Blocking studies were conducted for the heterodimer studies by co-injecting 100× of CNGRC (SEQ ID NO: 1) and RGDyK. Small animal PET/CT was performed at 1 hour post injection of tracers (FIGS. 15A-15C). The heterodimer CNGRC-(⁶⁸Ga)NOTA-RGDyK (“CNGRC” disclosed as SEQ ID NO: 1) showed improved in in vivo performance (such as longer blood retention, better tumor/non-tumor ratios) (FIG. 15A). Uptakes of the RGD-NGR heterodimer in muscle, blood, liver, spleen, kidney, pancrease, and orthotopic tumor were 0.10% ID/g, 0.10% ID/g, 1.8% ID/g, 1.10% ID/g, 2.2% ID/g, 0.36% ID/g, and 1.4% ID/g, respectively.

Full text: Click here

Patent 2024

1,4,7-triazacyclononane-N,N',N''-triacetic acid Animals BLOOD Blood Circulation Cardiac Arrest Cells Heterografts Kidney Liver Luciferases Malignant Neoplasms Mice, Inbred BALB C Mus Muscle Tissue Neoplasms Ovum Implantation Pancreas Pancrease Retention (Psychology) Scan, CT PET Spleen Tail Veins

Automated Radiosynthesis of ZD2-[68Ga-NOTA]

The radiosynthesis of ZD2-[⁶⁸Ga-NOTA] was performed in closed-system fully automated Scintomics GRP^® synthesizer (Furstenfeldbruck, Germany) as reported previously.8 (link) Briefly, ⁶⁸Ge/⁶⁸Ga generator (model IGG-100) was used as a source of radionuclide. In the process of automated synthesis, ⁶⁸Ga(III) was eluted from a generator with 0.1 M hydrochloric acid, and the eluent was diluted with water. The resulting solution was passed through the cationic exchange PS-H+ cartridge and subsequently eluted with 5 M sodium chloride solution into a pre-heated reactor containing ZD2-NOTA and HEPES buffer. The labeling was performed in 10 min at 125°C. After reaction, the reaction content was transferred onto C18 Plus Light SPE-cartridge, and the labeled ZD2-(⁶⁸Ga-NOTA) was eluted with a mixture of water for injection/ethanol (1/1, v/v) through the 0.22 µm membrane sterile filter into the final product vial. Finally, the product was diluted with a PBS buffer through the same sterile 0.22 µm membrane filter into the final product vial. Samples are then aseptically removed for quality control testing.

Sergeeva O., Zhang Y., Gao S., Chan E.R., Sergeev M., Iyer R., Sexton S., Avril N., Lu Z.R, & Lee Z. (2023). PET Imaging of Hepatocellular Carcinoma Using ZD2-(68Ga-NOTA). Journal of Hepatocellular Carcinoma, 10, 291-301.

Publication 2023

1,4,7-triazacyclononane-N,N',N''-triacetic acid Anabolism Buffers Cations Ethanol HEPES Hydrochloric acid Light Radioisotopes Saline Solution Strains Tissue, Membrane

In Vivo PET Imaging of Woodchucks

Woodchucks with an average weight of 3.5 kg were too large to fit into our microPET scanner and were placed prone in our clinical Ingenuity PET/CT scanner (Philips, Cleveland, OH) instead. Under 3% isoflurane gas anesthesia, the animals had a low-dose CT scan first, followed by i.v. injection of 37 ~ 56 MBq (1.0 ~ 1.5 mCi) ZD2-(⁶⁸Ga-NOTA) via the implanted venous access port. A dynamic PET acquisition in list mode started upon injection and lasted 60 min. The PET acquisition was re-binned into a total of 21 frames: 10×30 seconds, 5 X 1-min, 2 X 5-min frames, and 4×10 min, respectively, and reconstructed using iterative 3D-OSEM provided by the vendor incorporating the built-in CT-based attenuation correction. After the scan, the animals were euthanized for tissue harvesting including tumor and matched liver tissues. Some samples were fresh-frozen immediately for later use in PCR or Western blot, while others were fixed with formaldehyde for histology.
Standardized Uptake Value (SUV, normalized radiotracer uptake by body weight and injected tracer dose)35 (link) was calculated for regions of interest (ROIs) defined over focal uptakes of the ZD2 ligand as well as a nearby ROI over the liver background away from focal uptakes, similar to that used for computing FDG uptake.36 (link) Time activity curves in the unit of SUV were generated for these ROIs.

Publication 2023

1,4,7-triazacyclononane-N,N',N''-triacetic acid Anesthesia Animals Body Weight Formaldehyde Freezing Isoflurane Ligands Liver Neoplasm Metastasis Neoplasms Radionuclide Imaging Reading Frames Scan, CT PET Tissues Veins Western Blotting Woodchucks X-Ray Computed Tomography

Top products related to «1,4,7-triazacyclononane-N,N',N''-triacetic acid»

P scn bn nota by Macrocyclics

Sourced in United States

P-SCN-Bn-NOTA is a bifunctional chelator used for labeling proteins and other biomolecules with radioisotopes. It contains a p-isothiocyanatobenzyl group for conjugation and a NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) moiety for metal chelation.

Pd 10 column by GE Healthcare

Sourced in United States, United Kingdom, Germany, Sweden, Japan, Canada, Belgium

The PD-10 column is a size-exclusion chromatography column designed for desalting and buffer exchange of protein samples. It is commonly used to separate low molecular weight substances from high molecular weight compounds, such as proteins, in a rapid and efficient manner.

Gamma counter by PerkinElmer

Sourced in United States

The Gamma counter is a laboratory instrument used to measure the radioactivity of samples. It detects and quantifies gamma radiation emitted by radioactive isotopes present in the samples.

Chelex 100 resin by Merck Group

Sourced in United States, Australia

Chelex 100 resin is a chelating ion exchange resin composed of styrene divinylbenzene copolymer. It is used to selectively remove metal ions from aqueous solutions through the process of chelation.

S 2 4 isothiocyanatobenzyl 1 4 7 triazacyclononane 1 4 7 triacetic acid p scn bn nota by Macrocyclics

Sourced in United States

S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA) is a chemical compound used as a chelating agent in various laboratory applications. Its core function is to bind and stabilize metal ions, enabling their detection and analysis.

68ge 68ga generator by Eckert & Ziegler

Sourced in Germany, United States

The 68Ge/68Ga generator is a laboratory equipment used to produce gallium-68 (68Ga), a radioactive isotope. The generator utilizes the radioactive decay of germanium-68 (68Ge) to generate 68Ga, which can be extracted and used for various applications.

Inveon rodent model scanner by Siemens

Sourced in United States

The Inveon rodent model scanner is a preclinical imaging system designed for the study of small animals, such as mice and rats. It is a non-invasive tool that allows researchers to visualize and analyze various physiological processes and structures within the subject's body. The Inveon scanner utilizes advanced imaging technologies to capture high-resolution images and data, which can be used to support research in areas like drug development, disease modeling, and biomedical engineering.

Inveon by Siemens

Sourced in Germany, United States

The Inveon is a versatile and advanced pre-clinical imaging system designed for small animal research. It provides high-resolution imaging capabilities, supporting various modalities such as PET, SPECT, CT, and optical imaging. The Inveon is a robust and reliable platform that enables researchers to conduct non-invasive in vivo studies, facilitating the understanding of disease mechanisms and the evaluation of new therapies.

Pd 10 desalting column by GE Healthcare

Sourced in United States, United Kingdom, Sweden, Germany, Denmark, China, Switzerland, Belgium, Japan

The PD-10 desalting column is a laboratory equipment used for the separation and purification of biomolecules. It functions by removing salts, buffer components, or other small molecular weight substances from protein or nucleic acid samples, allowing for the recovery of the desired macromolecules in a purified form.

Scm peg5k mal by Creative PEGWorks

SCM-PEG5k-Mal is a polyethylene glycol (PEG) derivative with a maleimide functional group. It is used for the covalent attachment of PEG to other molecules, such as proteins or peptides, through thiol-maleimide chemistry.

What is 1,4,7-triazacyclononane-N,N',N''-triacetic acid used for?

1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA) is a versatile chelating agent with applications in chemistry, biology, and medicine. It is commonly used in the preparation of radiopharmaceuticals for medical imaging and therapy, as it can form stable complexes with a variety of metal ions. NOTA is also utilized as a chelating agent in various research and analytical applications, such as metal ion detection and separation.

What are the different types or variations of 1,4,7-triazacyclononane-N,N',N''-triacetic acid?

While 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA) is the most common form, there are also other variations of this compound. For example, some derivatives of NOTA have been developed, such as NODAGA (1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid) and NODAPA (1,4,7-triazacyclononane-1,4-diacetic acid-7-propionic acid), which offer slightly different chelation properties and applications.

How can PubCompare.ai help with the use of 1,4,7-triazacyclononane-N,N',N''-triacetic acid?

PubCompare.ai's AI-driven platfrom can assist researchers in optimizing their use of 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA) and its derivatives. The platform allows you to effeciently screen protocol literature, leveraging AI to pinpoint critical insights that can help you identify the most effective protocols related to NOTA for your specific research goals. By highlighting key differences in protocol effectiveness, PubCompare.ai can enable you to choose the best option for reproducibility and accuracy in your experiments.

What are some common challenges or considerations when using 1,4,7-triazacyclononane-N,N',N''-triacetic acid?

One of the key considerations when using 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA) is ensuring the proper complexation with the target metal ion. The chelation process can be affected by factors such as pH, reaction time, and the presence of other competing ligands. Additionally, the stability of the NOTA-metal complex can vary depending on the specific application, which is an importrant factor to consider when choosing the right NOTA derivative. Proper optimization and characterization of the NOTA-based compounds is crucial for achieving the desired results in research and medical applications.

More about "1,4,7-triazacyclononane-N,N',N''-triacetic acid"

1,4,7-Triazacyclononane-N,N',N''-Triacetic Acid (NOTA) is a versatile heterocyclic compound composed of a 9-membered ring containing three nitrogen atoms and three acetic acid groups attached to the nitrogens.
This versatile molecule, also known as p-SCN-Bn-NOTA, has a wide range of applications in chemistry, biology, and medicine.
As a chelating agent, NOTA is commonly used in the preparation of radiopharmaceuticals for medical imaging and therapy.
The compound's ability to form stable complexes with various metal ions, such as gallium-68 (68Ga) from a 68Ge/68Ga generator, makes it useful for labeling biomolecules like peptides and antibodies for positron emission tomography (PET) imaging.
In the laboratory, NOTA can be purified using a Chelex 100 resin column, and its concentration can be determined using a gamma counter.
The compound can also be conjugated to larger molecules, such as polyethylene glycol (PEG), to create constructs like S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA), which can be used for further functionalization or labeling.
NOTA's versatility extends to its use in small animal imaging, where it has been employed in Inveon rodent model scanners to study various biological processes and disease models.
The compound can also be desalted using a PD-10 desalting column before further analysis or application.
Overall, 1,4,7-Triazacyclononane-N,N',N''-Triacetic Acid (NOTA) is a powerful tool in the fields of chemistry, biology, and medicine, with a wide range of uses and the potential for further development and innovation.